Regulus Therapeutics

Regulus Therapeutics

Biotechnology Research

San Diego, CA 9,531 followers

About us

Regulus Therapeutics Inc. (Nasdaq:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a maturing microMarkersSM biomarkers platform and a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is located in San Diego, California and is led by a seasoned executive team experienced in corporate management, business, science, drug discovery and development. Regulus' scientific advisory board consists of world-class scientists and some of the foremost authorities in the field of microRNA research.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
San Diego, CA
Type
Public Company
Founded
2007
Specialties
microRNA and great company culture

Locations

Employees at Regulus Therapeutics

Updates

  • View organization page for Regulus Therapeutics, graphic

    9,531 followers

    We are very excited that the 2024 Nobel Prize in Physiology or Medicine was awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation. Our work developing novel oligonucleotide therapeutics that are designed to inhibit dysregulated microRNA targets follows on from this key discovery.

    View organization page for The Nobel Prize, graphic

    867,812 followers

    BREAKING NEWS The Nobel Assembly at the Karolinska Institutet has today decided to award the 2024 Nobel Prize in Physiology or Medicine to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation. This year’s Nobel Prize honours two scientists for their discovery of a fundamental principle governing how gene activity is regulated. The information stored within our chromosomes can be likened to an instruction manual for all cells in our body. Every cell contains the same chromosomes, so every cell contains exactly the same set of genes and exactly the same set of instructions. Yet, different cell types, such as muscle and nerve cells, have very distinct characteristics. How do these differences arise? The answer lies in gene regulation, which allows each cell to select only the relevant instructions. This ensures that only the correct set of genes is active in each cell type. This year’s medicine laureates Victor Ambros and Gary Ruvkun were interested in how different cell types develop. They discovered microRNA, a new class of tiny RNA molecules that play a crucial role in gene regulation. Their groundbreaking discovery revealed a completely new principle of gene regulation that turned out to be essential for multicellular organisms, including humans. It is now known that the human genome codes for over one thousand microRNAs. Their surprising discovery revealed an entirely new dimension to gene regulation. MicroRNAs are proving to be fundamentally important for how organisms develop and function.

    • No alternative text description for this image
  • View organization page for Regulus Therapeutics, graphic

    9,531 followers

    We are excited to announce that Ed Lee, our VP of Translational Biology, will be presenting a poster on the discovery of our lead candidate, RGLS8429, currently being evaluated for the treatment of autosomal dominant polycystic kidney disease at the Oligonucleotide Therapeutics Society Annual Meeting in Montreal tomorrow. The poster, entitled “Deciphering and overcoming off-target AMPAR inhibition of anti-miR oligonucleotide RGLS4326,” will be available for viewing at 3:45 p.m. ET on October 8 – come check it out! #ADPKD #ots24 #oligomeeting

    • No alternative text description for this image

Similar pages

Browse jobs

Funding

Regulus Therapeutics 15 total rounds

Last Round

Post IPO equity

US$ 100.0M

See more info on crunchbase